Ex vivo T-lymphopoiesis assays assisting corrective treatment choice for genetically undefined T-lymphocytopenia

Persistent selective T-lymphocytopenia is found both in SCID and congenital athymia. Without molecular diagnosis, it is challenging to determine whether HCT or thymus transplantation ought to be performed. Ex vivo T-lymphopoiesis assays have been proposed to assist clinical decision-making for genetically undefined patients. We investigated 20 T-lymphocytopenic patients, including 13 patients awaiting first-line treatment and 7 patients with failed immune reconstitution after previous HCT or thymus transplantation. Whilst developmental blocks in ex vivo T-lymphopoiesis indicated hematopoietic cell-intrinsic defects, successful T-lymphocyte differentiation required careful interpretation, in conjunction with clinical status, immunophenotyping, and genetic investigations. Of the 20 patients, 13 proceeded to treatment, with successful immune reconstitution observed in 4 of the 6 patients post-HCT and 4 of the 7 patients after thymus transplantation, the latter including two patients who had previously undergone HCT. Whilst further validation and standardization are required, we conclude that assessing ex vivo T-lymphopoiesis during the diagnostic pathway for genetically undefined T-lymphocytopenia improves patient outcomes by facilitating corrective treatment choice.

Authors

Institutions

Publication Details

Journal
Clinical Immunology
Published
2025-02-16
DOI
https://doi.org/10.1016/j.clim.2025.110453
Citations
1
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ex vivo T-lymphopoiesis assays assisting corrective treatment choice for genetically undefined T-lymphocytopenia

Pere Soler‐Palacín, Nufar Marcus, Andrew Richard Gennery, Irene Obiri-Yeboa et al.
1 citations
Clinical Immunology
Immunodeficiency and Autoimmune Disorders
0.80
article

Ex vivo T-lymphopoiesis assays assisting corrective treatment choice for genetically undefined T-lymphocytopenia

Pere Soler‐Palacín, Nufar Marcus, Andrew Richard Gennery, Irene Obiri-Yeboa, Herbert Pichler, Paul Torpiano, Adrian J. Thrasher, Fanette Bernard, Maarja Soomann, Sabrina Lizot, Sophie Hambleton, Theresa S. Cole, Neil J. Sebire, Alexandra Y. Kreins, Antonio Marzollo, Rajeev Rai, Zainab Golwala, Kaan Boztuǧ, Zohreh Nademi, Austen Worth, Stuart Adams, Anna Sellmer, Juan Moisés Ocampo‐Godínez, Ranjita Devi Moirangthem, Susanne Kricke, Matthew Buckland, Victoria Bordon, Mette Holm, Joris van Montfrans, Maaike Kusters, Alexandrine Garrigue, Kimberly Gilmour, Stefan Nierkens, Evey Howley, Jana Pachlopnik Schmid, Adam Klocperk, Coco de Koning, Isabelle André‐Schmutz, Grace Evans, Scott Hackett, Arnold Awuah, E. Graham Davies, Marta Martin Corredera, Helena Spiridou Goncalves
article en
1 citations

Abstract

Persistent selective T-lymphocytopenia is found both in SCID and congenital athymia. Without molecular diagnosis, it is challenging to determine whether HCT or thymus transplantation ought to be performed. Ex vivo T-lymphopoiesis assays have been proposed to assist clinical decision-making for genetically undefined patients. We investigated 20 T-lymphocytopenic patients, including 13 patients awaiting first-line treatment and 7 patients with failed immune reconstitution after previous HCT or thymus transplantation. Whilst developmental blocks in ex vivo T-lymphopoiesis indicated hematopoietic cell-intrinsic defects, successful T-lymphocyte differentiation required careful interpretation, in conjunction with clinical status, immunophenotyping, and genetic investigations. Of the 20 patients, 13 proceeded to treatment, with successful immune reconstitution observed in 4 of the 6 patients post-HCT and 4 of the 7 patients after thymus transplantation, the latter including two patients who had previously undergone HCT. Whilst further validation and standardization are required, we conclude that assessing ex vivo T-lymphopoiesis during the diagnostic pathway for genetically undefined T-lymphocytopenia improves patient outcomes by facilitating corrective treatment choice.

Clinical ImmunologyVol. 274
University of Padua (IT), Charles University (CZ), University Hospital in Motol (CZ)
Wellcome Trust, Great Ormond Street Hospital Charity, Medical Research Council
Zero hunger
Openalex Percentile: Top 31%
Immunodeficiency and Autoimmune Disorders
0.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.